Insights into the diverse effects of nitric oxide on tumor biology

Vitamins and Hormones

Volumn 96, Issue , 2014, Pages 265-298

  Vasudevan, Divya ^a   Thomas, Douglas D ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Angiogenesis; Cancer; Chemotherapeutics; Epigenetics; Epithelial mesenchymal transition; Iron; Metastasis; Nitric oxide; Nitric oxide synthase; Oxygen

Indexed keywords

NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OXYGEN;

GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; NEOPLASM; PHYSIOLOGY;

GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OXYGEN;

EID: 84906835026     PISSN: 00836729     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-800254-4.00011-8     Document Type: Chapter

References (134)

1. Ahn B., Ohshima H. Suppression of intestinal polyposis in Apc(Min/+) mice by inhibiting nitric oxide production. Cancer Research 2001, 61(23):8357-8360.
2. Ambs S., Bennett W.P., Merriam W.G., Ogunfusika M.O., Oser S.M., Harrington A.M., et al. Relationship between p53 mutations and inducible nitric oxide synthase expression in human colorectal cancer. Journal of the National Cancer Institute 1999, 91(1):86-88.
3. Ambs S., Merriam W.G., Bennett W.P., Felley-Bosco E., Ogunfusika M.O., Oser S.M., et al. Frequent nitric oxide synthase-2 expression in human colon adenomas: Implication for tumor angiogenesis and colon cancer progression. Cancer Research 1998, 58(2):334-341.
4. Anand P., Stamler J.S. Enzymatic mechanisms regulating protein S-nitrosylation: Implications in health and disease. Journal of Molecular Medicine 2012, 90(3):233-244. 10.1007/s00109-012-0878-z.
5. Babykutty S., Suboj P., Srinivas P., Nair A.S., Chandramohan K., Gopala S. Insidious role of nitric oxide in migration/invasion of colon cancer cells by upregulating MMP-2/9 via activation of cGMP-PKG-ERK signaling pathways. Clinical and Experimental Metastasis 2012, 29(5):471-492. 10.1007/s10585-012-9464-6.
6. Baritaki S., Huerta-Yepez S., Sahakyan A., Karagiannides I., Bakirtzi K., Jazirehi A., et al. Mechanisms of nitric oxide-mediated inhibition of EMT in cancer: Inhibition of the metastasis-inducer snail and induction of the metastasis-suppressor RKIP. Cell Cycle 2010, 9(24):4931-4940. 10.4161/cc.9.24.14229.
7. Beckman J.S., Beckman T.W., Chen J., Marshall P.A., Freeman B.A. Apparent hydroxyl radical production by peroxynitrite: Implications for endothelial injury from nitric oxide and superoxide. Proceedings of the National Academy of Sciences of the United States of America 1990, 87(4):1620-1624.
8. Belcheva A., Green B., Weiss A., Streutker C., Martin A. Elevated incidence of polyp formation in APC(Min/(+))Msh2(-)/(-) mice is independent of nitric oxide-induced DNA mutations. PLoS ONE 2013, 8(5):e65204. 10.1371/journal.pone.0065204.
9. Bian K., Ghassemi F., Sotolongo A., Siu A., Shauger L., Kots A., et al. NOS-2 signaling and cancer therapy. IUBMB Life 2012, 64(8):676-683. 10.1002/iub.1057.
10. Bingle L., Brown N.J., Lewis C.E. The role of tumour-associated macrophages in tumour progression: Implications for new anticancer therapies. Journal of Pathology 2002, 196(3):254-265. 10.1002/path.1027.
11. Bonavida B., Baritaki S. Dual role of NO donors in the reversal of tumor cell resistance and EMT: Downregulation of the NF-kappaB/Snail/YY1/RKIP circuitry. Nitric Oxide 2011, 24(1):1-7. 10.1016/j.niox.2010.10.001.
12. Bosworth C.A., Toledo J.C., Zmijewski J.W., Li Q., Lancaster J.R. Dinitrosyliron complexes and the mechanism(s) of cellular protein nitrosothiol formation from nitric oxide. Proceedings of the National Academy of Sciences of the United States of America 2009, 106(12):4671-4676. 10.1073/pnas.0710416106.
13. Brennan P.A., Dennis S., Poller D., Quintero M., Puxeddu R., Thomas G.J. Inducible nitric oxide synthase: Correlation with extracapsular spread and enhancement of tumor cell invasion in head and neck squamous cell carcinoma. Head and Neck 2008, 30(2):208-214. 10.1002/hed.20675.
14. Broholm H., Rubin I., Kruse A., Braendstrup O., Schmidt K., Skriver E.B., et al. Nitric oxide synthase expression and enzymatic activity in human brain tumors. Clinical Neuropathology 2003, 22(6):273-281.
15. Broniowska K.A., Hogg N. The chemical biology of S-nitrosothiols. Antioxidants and Redox Signaling 2012, 17(7):969-980. 10.1089/ars.2012.4590.
16. Buerk D.G. Nitric oxide regulation of microvascular oxygen. Antioxidants and Redox Signaling 2007, 9(7):829-843. 10.1089/ars.2007.1551.
17. Burke A.J., Sullivan F.J., Giles F.J., Glynn S.A. The yin and yang of nitric oxide in cancer progression. Carcinogenesis 2013, 34(3):503-512. 10.1093/carcin/bgt034.
18. Buss J.L., Torti F.M., Torti S.V. The role of iron chelation in cancer therapy. Current Medicinal Chemistry 2003, 10(12):1021-1034.
19. Carpenter A.W., Schoenfisch M.H. Nitric oxide release: Part II. Therapeutic applications. Chemical Society Reviews 2012, 41(10):3742-3752. 10.1039/c2cs15273h.
20. Case A.J., Madsen J.M., Motto D.G., Meyerholz D.K., Domann F.E. Manganese superoxide dismutase depletion in murine hematopoietic stem cells perturbs iron homeostasis, globin switching, and epigenetic control in erythrocyte precursor cells. Free Radical Biology and Medicine 2013, 56:17-27. 10.1016/j.freeradbiomed.2012.11.018.
21. Connelly S.T., Macabeo-Ong M., Dekker N., Jordan R.C., Schmidt B.L. Increased nitric oxide levels and iNOS over-expression in oral squamous cell carcinoma. Oral Oncology 2005, 41(3):261-267. 10.1016/j.oraloncology.2004.09.007.
22. Cyr A.R., Domann F.E. The redox basis of epigenetic modifications: From mechanisms to functional consequences. Antioxidants and Redox Signaling 2011, 15(2):551-589. 10.1089/ars.2010.3492.
23. Decker N.K., Abdelmoneim S.S., Yaqoob U., Hendrickson H., Hormes J., Bentley M., et al. Nitric oxide regulates tumor cell cross-talk with stromal cells in the tumor microenvironment of the liver. American Journal of Pathology 2008, 173(4):1002-1012. 10.2353/ajpath.2008.080158.
24. Deryugina E.I., Quigley J.P. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Reviews 2006, 25(1):9-34. 10.1007/s10555-006-7886-9.
25. Duda D.G., Fukumura D., Jain R.K. Role of eNOS in neovascularization: NO for endothelial progenitor cells. Trends in Molecular Medicine 2004, 10(4):143-145.
26. Edwards P., Cendan J.C., Topping D.B., Moldawer L.L., MacKay S., Copeland E., et al. Tumor cell nitric oxide inhibits cell growth in vitro, but stimulates tumorigenesis and experimental lung metastasis in vivo. Journal of Surgical Research 1996, 63(1):49-52. 10.1006/jsre.1996.0221.
27. Ellies L.G., Fishman M., Hardison J., Kleeman J., Maglione J.E., Manner C.K., et al. Mammary tumor latency is increased in mice lacking the inducible nitric oxide synthase. International Journal of Cancer 2003, 106(1):1-7. 10.1002/ijc.11178.
28. Erdman S.E., Rao V.P., Poutahidis T., Rogers A.B., Taylor C.L., Jackson E.A., et al. Nitric oxide and TNF-alpha trigger colonic inflammation and carcinogenesis in Helicobacter hepaticus-infected, Rag2-deficient mice. Proceedings of the National Academy of Sciences of the United States of America 2009, 106(4):1027-1032. 10.1073/pnas.0812347106.
29. Espey M.G., Thomas D.D., Miranda K.M., Wink D.A. Focusing of nitric oxide mediated nitrosation and oxidative nitrosylation as a consequence of reaction with superoxide. Proceedings of the National Academy of Sciences of the United States of America 2002, 99(17):11127-11132. 10.1073/pnas.152157599.
30. Espey M.G., Xavier S., Thomas D.D., Miranda K.M., Wink D.A. Direct real-time evaluation of nitration with green fluorescent protein in solution and within human cells reveals the impact of nitrogen dioxide vs. peroxynitrite mechanisms. Proceedings of the National Academy of Sciences of the United States of America 2002, 99(6):3481-3486. 10.1073/pnas.062604199.
31. Ford P.C., Wink D.A., Stanbury D.M. Autoxidation kinetics of aqueous nitric oxide. FEBS Letters 1993, 326(1-3):1-3. 10.1016/0014-5793(93)81748-O.
32. Forrester K., Ambs S., Lupold S.E., Kapust R.B., Spillare E.A., Weinberg W.C., et al. Nitric oxide-induced p53 accumulation and regulation of inducible nitric oxide synthase expression by wild-type p53. Proceedings of the National Academy of Sciences of the United States of America 1996, 93(6):2442-2447.
33. Fukumura D., Kashiwagi S., Jain R.K. The role of nitric oxide in tumour progression. Nature Reviews. Cancer 2006, 6(7):521-534. 10.1038/nrc1910.
34. Gao J., Liu X., Rigas B. Nitric oxide-donating aspirin induces apoptosis in human colon cancer cells through induction of oxidative stress. Proceedings of the National Academy of Sciences of the United States of America 2005, 102(47):17207-17212. 10.1073/pnas.0506893102.
35. Glynn S.A., Boersma B.J., Dorsey T.H., Yi M., Yfantis H.G., Ridnour L.A., et al. Increased NOS2 predicts poor survival in estrogen receptor-negative breast cancer patients. Journal of Clinical Investigation 2010, 120(11):3843-3854. 10.1172/JCI42059.
36. Gow A.J., Farkouh C.R., Munson D.A., Posencheg M.A., Ischiropoulos H. Biological significance of nitric oxide-mediated protein modifications. American Journal of Physiology. Lung Cellular and Molecular Physiology 2004, 287(2):L262-L268. 10.1152/ajplung.00295.2003.
37. Grimm E.A., Ellerhorst J., Tang C.H., Ekmekcioglu S. Constitutive intracellular production of iNOS and NO in human melanoma: Possible role in regulation of growth and resistance to apoptosis. Nitric Oxide 2008, 19(2):133-137. 10.1016/j.niox.2008.04.009.
38. Hagos G.K., Carroll R.E., Kouznetsova T., Li Q., Toader V., Fernandez P.A., et al. Colon cancer chemoprevention by a novel NO chimera that shows anti-inflammatory and antiproliferative activity in vitro and in vivo. Molecular Cancer Therapeutics 2007, 6(8):2230-2239. 10.1158/1535-7163.MCT-07-0069.
39. Hanahan D., Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 86(3):353-364. 10.1016/S0092-8674(00)80108-7.
40. Harada K., Supriatno, Kawaguchi S., Tomitaro O., Yoshida H., Sato M. Overexpression of iNOS gene suppresses the tumorigenicity and metastasis of oral cancer cells. In Vivo 2004, 18(4):449-455.
41. Hickok J.R., Sahni S., Mikhed Y., Bonini M.G., Thomas D.D. Nitric oxide suppresses tumor cell migration through N-Myc downstream-regulated gene-1 (NDRG1) expression: Role of chelatable iron. Journal of Biological Chemistry 2011, 286(48):41413-41424. 10.1074/jbc.M111.287052.
42. Hickok J.R., Sahni S., Shen H., Arvind A., Antoniou C., Fung L.W., et al. Dinitrosyliron complexes are the most abundant nitric oxide-derived cellular adduct: Biological parameters of assembly and disappearance. Free Radical Biology and Medicine 2011, 51(8):1558-1566. 10.1016/j.freeradbiomed.2011.06.030.
43. Hickok J.R., Thomas D.D. Nitric oxide and cancer therapy: The emperor has NO clothes. Current Pharmaceutical Design 2010, 16(4):381-391.
44. Hickok J.R., Vasudevan D., Antholine W.E., Thomas D.D. Nitric oxide modifies global histone methylation by inhibiting Jumonji C domain-containing demethylases. Journal of Biological Chemistry 2013, 288(22):16004-16015. 10.1074/jbc.M112.432294.
45. Hickok J.R., Vasudevan D., Jablonski K., Thomas D.D. Oxygen dependence of nitric oxide-mediated signaling. Redox Biology 2013, 1(1):203-209. 10.1016/j.redox.2012.11.002.
46. Hickok J.R., Vasudevan D., Thatcher G.R., Thomas D.D. Is S-nitrosocysteine a true surrogate for nitric oxide?. Antioxidants and Redox Signaling 2012, 17(7):962-968. 10.1089/ars.2012.4543.
47. Hitchler M.J., Domann F.E. Metabolic defects provide a spark for the epigenetic switch in cancer. Free Radical Biology and Medicine 2009, 47(2):115-127. 10.1016/j.freeradbiomed.2009.04.010.
48. Hitchler M.J., Domann F.E. Redox regulation of the epigenetic landscape in cancer: A role for metabolic reprogramming in remodeling the epigenome. Free Radical Biology and Medicine 2012, 53(11):2178-2187. 10.1016/j.freeradbiomed.2012.09.028.
49. Hitchler M.J., Wikainapakul K., Yu L., Powers K., Attatippaholkun W., Domann F.E. Epigenetic regulation of manganese superoxide dismutase expression in human breast cancer cells. Epigenetics 2006, 1(4):163-171. 10.4161/epi.1.4.3401.
50. Hofseth L.J., Saito S., Hussain S.P., Espey M.G., Miranda K.M., Araki Y., et al. Nitric oxide-induced cellular stress and p53 activation in chronic inflammation. Proceedings of the National Academy of Sciences of the United States of America 2003, 100(1):143-148. 10.1073/pnas.0237083100.
51. Hojfeldt J.W., Agger K., Helin K. Histone lysine demethylases as targets for anticancer therapy. Nature Reviews. Drug Discovery 2013, 12(12):917-930. 10.1038/nrd4154.
52. Hussain S.P., Amstad P., Raja K., Ambs S., Nagashima M., Bennett W.P., et al. Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: A cancer-prone chronic inflammatory disease. Cancer Research 2000, 60(13):3333-3337.
53. Ignarro L.J., Buga G.M., Wood K.S., Byrns R.E., Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proceedings of the National Academy of Sciences of the United States of America 1987, 84(24):9265-9269.
54. Isenberg J.S., Ridnour L.A., Perruccio E.M., Espey M.G., Wink D.A., Roberts D.D. Thrombospondin-1 inhibits endothelial cell responses to nitric oxide in a cGMP-dependent manner. Proceedings of the National Academy of Sciences of the United States of America 2005, 102(37):13141-13146. 10.1073/pnas.0502977102.
55. Ishii Y., Ogura T., Tatemichi M., Fujisawa H., Otsuka F., Esumi H. Induction of matrix metalloproteinase gene transcription by nitric oxide and mechanisms of MMP-1 gene induction in human melanoma cell lines. International Journal of Cancer 2003, 103(2):161-168. 10.1002/ijc.10808.
56. Jaakkola P., Mole D.R., Tian Y.M., Wilson M.I., Gielbert J., Gaskell S.J., et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001, 292(5516):468-472. 10.1126/science.1059796.
57. Jadeski L.C., Hum K.O., Chakraborty C., Lala P.K. Nitric oxide promotes murine mammary tumour growth and metastasis by stimulating tumour cell migration, invasiveness and angiogenesis. International Journal of Cancer 2000, 86(1):30-39. 10.1002/(SICI)1097-0215(20000401)86:1<30::AID-IJC5>3.0.CO;2-I.
58. Jadeski L.C., Lala P.K. Nitric oxide synthase inhibition by N(G)-nitro-L-arginine methyl ester inhibits tumor-induced angiogenesis in mammary tumors. American Journal of Pathology 1999, 155(4):1381-1390. 10.1016/S0002-9440(10)65240-6.
59. Jenkins D.C., Charles I.G., Thomsen L.L., Moss D.W., Holmes L.S., Baylis S.A., et al. Roles of nitric oxide in tumor growth. Proceedings of the National Academy of Sciences of the United States of America 1995, 92(10):4392-4396.
60. Jespersen C., Doller A., Akool el S., Bachmann M., Muller R., Gutwein P., et al. Molecular mechanisms of nitric oxide-dependent inhibition of TPA-induced matrix metalloproteinase-9 (MMP-9) in MCF-7 cells. Journal of Cellular Physiology 2009, 219(2):276-287. 10.1002/jcp.21658.
61. Jones M.K., Tsugawa K., Tarnawski A.S., Baatar D. Dual actions of nitric oxide on angiogenesis: Possible roles of PKC, ERK, and AP-1. Biochemical and Biophysical Research Communications 2004, 318(2):520-528. 10.1016/j.bbrc.2004.04.055.
62. Jourd'heuil D., Miranda K.M., Kim S.M., Espey M.G., Vodovotz Y., Laroux S., et al. The oxidative and nitrosative chemistry of the nitric oxide/superoxide reaction in the presence of bicarbonate. Archives of Biochemistry and Biophysics 1999, 365(1):92-100. 10.1006/abbi.1999.1143.
63. Kisley L.R., Barrett B.S., Bauer A.K., Dwyer-Nield L.D., Barthel B., Meyer A.M., et al. Genetic ablation of inducible nitric oxide synthase decreases mouse lung tumorigenesis. Cancer Research 2002, 62(23):6850-6856.
64. Kiziltepe T., Hideshima T., Ishitsuka K., Ocio E.M., Raje N., Catley L., et al. JS-K, a GST-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cells. Blood 2007, 110(2):709-718. 10.1182/blood-2006-10-052845.
65. Knowles H.J., Mole D.R., Ratcliffe P.J., Harris A.L. Normoxic stabilization of hypoxia-inducible factor-1alpha by modulation of the labile iron pool in differentiating U937 macrophages: Effect of natural resistance-associated macrophage protein 1. Cancer Research 2006, 66(5):2600-2607. 10.1158/0008-5472.CAN-05-2351.
66. Kooistra S.M., Helin K. Molecular mechanisms and potential functions of histone demethylases. Nature Reviews. Molecular Cell Biology 2012, 13(5):297-311. 10.1038/nrm3327.
67. Kouzarides T. Chromatin modifications and their function. Cell 2007, 128(4):693-705. 10.1016/j.cell.2007.02.005.
68. Kroncke K.D. Zinc finger proteins as molecular targets for nitric oxide-mediated gene regulation. Antioxidants and Redox Signaling 2001, 3(4):565-575. 10.1089/15230860152542934.
69. Lancaster J. Reactivity and diffusivity of nitrogen oxides in mammalian biology. Signal transduction by reactive oxygen and nitrogen species: pathways and chemical principles 2003, 53-79. Springer, Netherlands. H.J. Forman, J. Fukuto, M. Torres (Eds.).
70. Laval F., Wink D.A., Laval J. A discussion of mechanisms of NO genotoxicity: Implication of inhibition of DNA repair proteins. Reviews of Physiology, Biochemistry and Pharmacology 1997, 131:175-191.
71. Le X., Wei D., Huang S., Lancaster J.R., Xie K. Nitric oxide synthase II suppresses the growth and metastasis of human cancer regardless of its up-regulation of protumor factors. Proceedings of the National Academy of Sciences of the United States of America 2005, 102(24):8758-8763. 10.1073/pnas.0409581102.
72. Lim K.H., Ancrile B.B., Kashatus D.F., Counter C.M. Tumour maintenance is mediated by eNOS. Nature 2008, 452(7187):646-649. 10.1038/nature06778.
73. Liu R.H., Hotchkiss J.H. Potential genotoxicity of chronically elevated nitric oxide: A review. Mutational Research 1995, 339(2):73-89. 10.1016/0165-1110(95)90004-7.
74. Liu X., Miller M.J., Joshi M.S., Thomas D.D., Lancaster J.R. Accelerated reaction of nitric oxide with O2 within the hydrophobic interior of biological membranes. Proceedings of the National Academy of Sciences of the United States of America 1998, 95(5):2175-2179.
75. Lok H.C., Suryo Rahmanto Y., Hawkins C.L., Kalinowski D.S., Morrow C.S., Townsend A.J., et al. Nitric oxide storage and transport in cells are mediated by glutathione S-transferase P1-1 and multidrug resistance protein 1 via dinitrosyl iron complexes. Journal of Biological Chemistry 2012, 287(1):607-618. 10.1074/jbc.M111.310987.
76. Lymar S.V., Khairutdinov R.F., Hurst J.K. Hydroxyl radical formation by O-O bond homolysis in peroxynitrous acid. Inorganic Chemistry 2003, 42(17):5259-5266. 10.1021/ic030104l.
77. Maciag A.E., Holland R.J., Robert Cheng Y.S., Rodriguez L.G., Saavedra J.E., Anderson L.M., et al. Nitric oxide-releasing prodrug triggers cancer cell death through deregulation of cellular redox balance. Redox Biology 2013, 1(1):115-124. 10.1016/j.redox.2012.12.002.
78. Mason M.G., Nicholls P., Wilson M.T., Cooper C.E. Nitric oxide inhibition of respiration involves both competitive (heme) and noncompetitive (copper) binding to cytochrome c oxidase. Proceedings of the National Academy of Sciences of the United States of America 2006, 103(3):708-713. 10.1073/pnas.0506562103.
79. Miller M.R., Megson I.L. Recent developments in nitric oxide donor drugs. British Journal of Pharmacology 2007, 151(3):305-321. 10.1038/sj.bjp.0707224.
80. Nam K.T., Oh S.Y., Ahn B., Kim Y.B., Jang D.D., Yang K.H., et al. Decreased Helicobacter pylori associated gastric carcinogenesis in mice lacking inducible nitric oxide synthase. Gut 2004, 53(9):1250-1255. 10.1136/gut.2003.030684.
81. Namkoong S., Lee S.J., Kim C.K., Kim Y.M., Chung H.T., Lee H., et al. Prostaglandin E2 stimulates angiogenesis by activating the nitric oxide/cGMP pathway in human umbilical vein endothelial cells. Experimental and Molecular Medicine 2005, 37(6):588-600. 10.1038/emm.2005.72.
82. Nanni S., Aiello A., Re A., Guffanti A., Benvenuti V., Colussi C., et al. Estrogen-dependent dynamic profile of eNOS-DNA associations in prostate cancer. PLoS ONE 2013, 8(5):e62522. 10.1371/journal.pone.0062522.
83. Nguyen T., Brunson D., Crespi C.L., Penman B.W., Wishnok J.S., Tannenbaum S.R. DNA damage and mutation in human cells exposed to nitric oxide in vitro. Proceedings of the National Academy of Sciences of the United States of America 1992, 89(7):3030-3034.
84. Nishida N., Yano H., Nishida T., Kamura T., Kojiro M. Angiogenesis in cancer. Vascular Health and Risk Management 2006, 2(3):213-219.
85. Okayama H., Saito M., Oue N., Weiss J.M., Stauffer J., Takenoshita S., et al. NOS2 enhances KRAS-induced lung carcinogenesis, inflammation and microRNA-21 expression. International Journal of Cancer 2013, 132(1):9-18. 10.1002/ijc.27644.
86. Orucevic A., Bechberger J., Green A.M., Shapiro R.A., Billiar T.R., Lala P.K. Nitric-oxide production by murine mammary adenocarcinoma cells promotes tumor-cell invasiveness. International Journal of Cancer 1999, 81(6):889-896. 10.1002/(SICI)1097-0215(19990611)81:6<889::AID-IJC9>3.0.CO;2-2.
87. Papapetropoulos A., Garcia-Cardena G., Madri J.A., Sessa W.C. Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. Journal of Clinical Investigation 1997, 100(12):3131-3139. 10.1172/JCI119868.
88. Petrat F., de Groot H., Sustmann R., Rauen U. The chelatable iron pool in living cells: A methodically defined quantity. Biological Chemistry 2002, 383(3-4):489-502. 10.1515/BC.2002.051.
89. Pipili-Synetos E., Sakkoula E., Haralabopoulos G., Andriopoulou P., Peristeris P., Maragoudakis M.E. Evidence that nitric oxide is an endogenous antiangiogenic mediator. British Journal of Pharmacology 1994, 111(3):894-902.
90. Raspollini M.R., Amunni G., Villanucci A., Boddi V., Baroni G., Taddei A., et al. Expression of inducible nitric oxide synthase and cyclooxygenase-2 in ovarian cancer: Correlation with clinical outcome. Gynecologic Oncology 2004, 92(3):806-812. 10.1016/j.ygyno.2003.12.023.
91. Ridnour L.A., Isenberg J.S., Espey M.G., Thomas D.D., Roberts D.D., Wink D.A. Nitric oxide regulates angiogenesis through a functional switch involving thrombospondin-1. Proceedings of the National Academy of Sciences of the United States of America 2005, 102(37):13147-13152. 10.1073/pnas.0502979102.
92. Ridnour L.A., Thomas D.D., Donzelli S., Espey M.G., Roberts D.D., Wink D.A., et al. The biphasic nature of nitric oxide responses in tumor biology. Antioxidants and Redox Signaling 2006, 8(7-8):1329-1337. 10.1089/ars.2006.8.1329.
93. Rigas B. Novel agents for cancer prevention based on nitric oxide. Biochemical Society Transactions 2007, 35(Pt 5):1364-1368. 10.1042/BST0351364.
94. Roberts D.D., Isenberg J.S., Ridnour L.A., Wink D.A. Nitric oxide and its gatekeeper thrombospondin-1 in tumor angiogenesis. Clinical Cancer Research 2007, 13(3):795-798. 10.1158/1078-0432.CCR-06-1758.
95. Salgo M.G., Stone K., Squadrito G.L., Battista J.R., Pryor W.A. Peroxynitrite causes DNA nicks in plasmid pBR322. Biochemical and Biophysical Research Communications 1995, 210(3):1025-1030. 10.1006/bbrc.1995.1759.
96. Scott D.J., Hull M.A., Cartwright E.J., Lam W.K., Tisbury A., Poulsom R., et al. Lack of inducible nitric oxide synthase promotes intestinal tumorigenesis in the Apc(Min/+) mouse. Gastroenterology 2001, 121(4):889-899. 10.1053/gast.2001.27994.
97. Shi Q., Xiong Q., Wang B., Le X., Khan N.A., Xie K. Influence of nitric oxide synthase II gene disruption on tumor growth and metastasis. Cancer Research 2000, 60(10):2579-2583.
98. Sidorkina O., Espey M.G., Miranda K.M., Wink D.A., Laval J. Inhibition of poly(ADP-RIBOSE) polymerase (PARP) by nitric oxide and reactive nitrogen oxide species. Free Radical Biology and Medicine 2003, 35(11):1431-1438. 10.1016/j.freeradbiomed.2003.08.015.
99. Siegert A., Rosenberg C., Schmitt W.D., Denkert C., Hauptmann S. Nitric oxide of human colorectal adenocarcinoma cell lines promotes tumour cell invasion. British Journal of Cancer 2002, 86(8):1310-1315. 10.1038/sj.bjc.6600224.
100. Siemens D.R., Heaton J.P., Adams M.A., Kawakami J., Graham C.H. Phase II study of nitric oxide donor for men with increasing prostate-specific antigen level after surgery or radiotherapy for prostate cancer. Urology 2009, 74(4):878-883. 10.1016/j.urology.2009.03.004.
101. Stamler J.S., Jaraki O., Osborne J., Simon D.I., Keaney J., Vita J., et al. Nitric oxide circulates in mammalian plasma primarily as an S-nitroso adduct of serum albumin. Proceedings of the National Academy of Sciences of the United States of America 1992, 89(16):7674-7677.
102. Stuehr D.J., Santolini J., Wang Z.Q., Wei C.C., Adak S. Update on mechanism and catalytic regulation in the NO synthases. Journal of Biological Chemistry 2004, 279(35):36167-36170. 10.1074/jbc.R400017200.
103. Switzer C.H., Glynn S.A., Cheng R.Y., Ridnour L.A., Green J.E., Ambs S., et al. S-nitrosylation of EGFR and Src activates an oncogenic signaling network in human basal-like breast cancer. Molecular Cancer Research 2012, 10(9):1203-1215. 10.1158/1541-7786.MCR-12-0124.
104. Tanese K., Grimm E.A., Ekmekcioglu S. The role of melanoma tumor-derived nitric oxide in the tumor inflammatory microenvironment: Its impact on the chemokine expression profile, including suppression of CXCL10. International Journal of Cancer 2012, 131(4):891-901. 10.1002/ijc.26451.
105. Tanriover N., Ulu M.O., Isler C., Durak H., Oz B., Uzan M., et al. Neuronal nitric oxide synthase expression in glial tumors: Correlation with malignancy and tumor proliferation. Neurological Research 2008, 30(9):940-944. 10.1179/174313208X319099.
106. Thiery J.P. Epithelial-mesenchymal transitions in tumour progression. Nature Reviews. Cancer 2002, 2(6):442-454. 10.1038/nrc822.
107. Thiery J.P. Epithelial-mesenchymal transitions in development and pathologies. Current Opinion in Cell Biology 2003, 15(6):740-746. 10.1016/j.ceb.2003.10.006.
108. Thomas D.D., Espey M.G., Ridnour L.A., Hofseth L.J., Mancardi D., Harris C.C., et al. Hypoxic inducible factor 1alpha, extracellular signal-regulated kinase, and p53 are regulated by distinct threshold concentrations of nitric oxide. Proceedings of the National Academy of Sciences of the United States of America 2004, 101(24):8894-8899. 10.1073/pnas.0400453101.
109. Thomas D.D., Espey M.G., Vitek M.P., Miranda K.M., Wink D.A. Protein nitration is mediated by heme and free metals through Fenton-type chemistry: An alternative to the NO/O2- reaction. Proceedings of the National Academy of Sciences of the United States of America 2002, 99(20):12691-12696. 10.1073/pnas.202312699.
110. Thomas D.D., Liu X., Kantrow S.P., Lancaster J.R. The biological lifetime of nitric oxide: Implications for the perivascular dynamics of NO and O2. Proceedings of the National Academy of Sciences of the United States of America 2001, 98(1):355-360. 10.1073/pnas.011379598.
111. Thomas D.D., Ridnour L.A., Espey M.G., Donzelli S., Ambs S., Hussain S.P., et al. Superoxide fluxes limit nitric oxide-induced signaling. Journal of Biological Chemistry 2006, 281(36):25984-25993. 10.1074/jbc.M602242200.
112. Thomas D.D., Ridnour L.A., Isenberg J.S., Flores-Santana W., Switzer C.H., Donzelli S., et al. The chemical biology of nitric oxide: Implications in cellular signaling. Free Radical Biology and Medicine 2008, 45(1):18-31. 10.1016/j.freeradbiomed.2008.03.020.
113. Toledo J.C., Bosworth C.A., Hennon S.W., Mahtani H.A., Bergonia H.A., Lancaster J.R. Nitric oxide-induced conversion of cellular chelatable iron into macromolecule-bound paramagnetic dinitrosyliron complexes. Journal of Biological Chemistry 2008, 283(43):28926-28933. 10.1074/jbc.M707862200.
114. Torti S.V., Torti F.M. Ironing out cancer. Cancer Research 2011, 71(5):1511-1514. 10.1158/0008-5472.CAN-10-3614.
115. Toyokuni S. Role of iron in carcinogenesis: Cancer as a ferrotoxic disease. Cancer Science 2009, 100(1):9-16. 10.1111/j.1349-7006.2008.01001.x.
116. Tsurumi Y., Murohara T., Krasinski K., Chen D., Witzenbichler B., Kearney M., et al. Reciprocal relation between VEGF and NO in the regulation of endothelial integrity. Nature Medicine 1997, 3(8):879-886.
117. Urbich C., Reissner A., Chavakis E., Dernbach E., Haendeler J., Fleming I., et al. Dephosphorylation of endothelial nitric oxide synthase contributes to the anti-angiogenic effects of endostatin. FASEB Journal 2002, 16(7):706-708. 10.1096/fj.01-0637fje.
118. Vakkala M., Kahlos K., Lakari E., Paakko P., Kinnula V., Soini Y. Inducible nitric oxide synthase expression, apoptosis, and angiogenesis in in situ and invasive breast carcinomas. Clinical Cancer Research 2000, 6(6):2408-2416.
119. Vanin A.F., Malenkova I.V., Serezhenkov V.A. Iron catalyzes both decomposition and synthesis of S-nitrosothiols: Optical and electron paramagnetic resonance studies. Nitric Oxide 1997, 1(3):191-203. 10.1006/niox.1997.0122.
120. Vithayathil A.J., Ternberg J.L., Commoner B. Changes in electron spin resonance signals of rat liver during chemical carcinogenesis. Nature 1965, 207(5003):1246-1249.
121. Vyas-Read S., Shaul P.W., Yuhanna I.S., Willis B.C. Nitric oxide attenuates epithelial-mesenchymal transition in alveolar epithelial cells. American Journal of Physiology. Lung Cellular and Molecular Physiology 2007, 293(1):L212-L221. 10.1152/ajplung.00475.2006.
122. Wei D., Richardson E.L., Zhu K., Wang L., Le X., He Y., et al. Direct demonstration of negative regulation of tumor growth and metastasis by host-inducible nitric oxide synthase. Cancer Research 2003, 63(14):3855-3859.
123. Wink D.A., Hanbauer I., Grisham M.B., Laval F., Nims R.W., Laval J., et al. Chemical biology of nitric oxide: Regulation and protective and toxic mechanisms. Current Topics in Cellular Regulation 1996, 34:159-187.
124. Wink D.A., Kasprzak K.S., Maragos C.M., Elespuru R.K., Misra M., Dunams T.M., et al. DNA deaminating ability and genotoxicity of nitric oxide and its progenitors. Science 1991, 254(5034):1001-1003.
125. Wink D.A., Laval J. The Fpg protein, a DNA repair enzyme, is inhibited by the biomediator nitric oxide in vitro and in vivo. Carcinogenesis 1994, 15(10):2125-2129.
126. Wink D.A., Ridnour L.A., Hussain S.P., Harris C.C. The reemergence of nitric oxide and cancer. Nitric Oxide 2008, 19(2):65-67. 10.1016/j.niox.2008.05.003.
127. Wink D.A., Vodovotz Y., Laval J., Laval F., Dewhirst M.W., Mitchell J.B. The multifaceted roles of nitric oxide in cancer. Carcinogenesis 1998, 19(5):711-721.
128. Xie K., Huang S., Dong Z., Juang S.H., Gutman M., Xie Q.W., et al. Transfection with the inducible nitric oxide synthase gene suppresses tumorigenicity and abrogates metastasis by K-1735 murine melanoma cells. Journal of Experimental Medicine 1995, 181(4):1333-1343.
129. Yermilov V., Rubio J., Becchi M., Friesen M.D., Pignatelli B., Ohshima H. Formation of 8-nitroguanine by the reaction of guanine with peroxynitrite in vitro. Carcinogenesis 1995, 16(9):2045-2050.
130. Yermilov V., Rubio J., Ohshima H. Formation of 8-nitroguanine in DNA treated with peroxynitrite in vitro and its rapid removal from DNA by depurination. FEBS Letters 1995, 376(3):207-210. 10.1016/0014-5793(95)01281-6.
131. Ying L., Hofseth L.J. An emerging role for endothelial nitric oxide synthase in chronic inflammation and cancer. Cancer Research 2007, 67(4):1407-1410. 10.1158/0008-5472.CAN-06-2149.
132. Yu Y., Gutierrez E., Kovacevic Z., Saletta F., Obeidy P., Suryo Rahmanto Y., et al. Iron chelators for the treatment of cancer. Current Medicinal Chemistry 2012, 19(17):2689-2702. 10.2174/092986712800609706.
133. Zhou J., Schmid T., Brune B. HIF-1alpha and p53 as targets of NO in affecting cell proliferation, death and adaptation. Current Molecular Medicine 2004, 4(7):741-751.
134. Ziche M., Morbidelli L., Masini E., Amerini S., Granger H.J., Maggi C.A., et al. Nitric oxide mediates angiogenesis in vivo and endothelial cell growth and migration in vitro promoted by substance P. Journal of Clinical Investigation 1994, 94(5):2036-2044. 10.1172/JCI117557.